Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2002-09-09
2008-08-26
Prouty, Rebecca E. (Department: 1652)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085400, C424S085100, C424S651000, C514S503000
Reexamination Certificate
active
07416723
ABSTRACT:
In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon β, interferon γ, or granulocyte/macrophage colony stimulating factor.
REFERENCES:
patent: 5334374 (1994-08-01), Hartley et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5859065 (1999-01-01), Brandes
patent: 6020179 (2000-02-01), Goli
patent: 6143765 (2000-11-01), Tang et al.
patent: 6197306 (2001-03-01), Murali
patent: 6207145 (2001-03-01), Tovey
patent: 6258582 (2001-07-01), Acton
patent: 6388076 (2002-05-01), Mjalli et al.
patent: 6410586 (2002-06-01), Moller et al.
patent: 6569853 (2003-05-01), Borisy et al.
patent: 6693125 (2004-02-01), Borisy et al.
patent: WO 00/21506 (2000-04-01), None
patent: WO 00/21506 (2000-04-01), None
Almeida et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. J Infect Dis. Nov. 1999;180(5):1735-7.
Snapper et al. Stilbamidine and Pentamidine in multiple myeloma, JAMA, 1947, 133(3): 157-161.
Shankar et al. Leishmania major: differential resistance to infection in C57BL/6 (high interferon-alpha/beta) and congenic B6.C-H-28c (low interferon-alpha/beta) mice, Exp Parasitol. Nov. 1996; 84(2): 136-43.
Adachi, M., E.H. Fishcher, J. Ihle, K. Imai, F. Jirik, B. Neel, T. Pawson, S. Shen, M. Thomas, A. Ullrich, and Z. Zhao. Mammaliam SH2-containing protein tyrosine phosphatases.
Alexander, J., K. C. Carter, N. A1-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30:2935.
Bleumer, I. E. Oosterwijk, P. DeMulder, and P. F. Mulders. 2003. Immunotherapy for renal cell carcinoma. Eur Urol 44:75.
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Fralnick, H. R. and Sultan, C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med., 103: 460-2, 1985.
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Fralnick, H. R. and Sultan, C. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br J Haematol, 78: 325-9, 1991.
Bergamaschi, G., Carlo-Stella, C., Cazzola, M., De Fazio, P., Pedrazzoli, P., Peverali, F. A. and Della Valle, G. Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. Leukemia, 4: 426-30, 1990.
Berman, J. D. and D. J. Wyler. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect Dis., 142: 83.
Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 10:560.
Bittorf, T., Seiler, J., Zhang, Z., Jaster, R. and Brock, J. SHP1 protein tyrosine phospahtase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem, 380: 1201-9, 1999.
Blanchette, J., N. Racette, R. Faure, K. A. Siminovitch, and M. Olivier. 1999. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation. Eur J Immunol 29:3737.
Bloomfield, C.D. and Brunning R. D. The revised French-American-British classification of acute myeloid leukemia: is new better? Ann Intern Med., 103: 614-6, 1985.
Blume-Jensen, P. and Hunter, T. Oncogenic Kinase signaling. Nature, 411: 355-365, 2001.
Borden, E. C., Lindner, D., Dreicer, R., Hussein, M. and Peereboom, D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol, 10: 125-44, 2000.
Breitman, T. R, Selonick, S. E. and Collins, S. J. Introduction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA, 77:2936-40, 1980.
Burke, T., Jr., and Z.Y. Zhang. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 47: 225, 1998.
Burshtyn, D. N., Scharenberg, A. M., Wagtmann, N., Rajagopalan, S., Berrada, K., Yi, T., Kinet, J. P. and Long, E. O. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity, 4:77-85, 1996.
Burshtyn, D. N., Yang, W., Yi, T. and Long, E. O. A novel phosphotyrosine motif with a critical amino acid at position-2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1 [In Process Citation]. J. Biol Chem, 272: 13066-72, 1997.
Cailleau, R., Young, R., Olive, M. and Reeves, W., Jr. Breast tumor cell lines from pleural effusions. J. Natl Cancer Inst., 53: 661-74, 1974.
Carini, C., Hudspith, B. N. and Brostoff, J. Effect of prostaglandins and cyclic nucleotides on growth and immunoglobin secretion of two IgE myeloma cell lines. 43: 257-60, 1981.
Carter, J.D., B. G. Neel, and U. Lorenz. The tyrosine phosphatase SHP-1 influences thymoctye selection by setting TCR signaling thresholds. Int Immunol 11:1999-2013.
Chakravortty, D., Kato, Y., Sugiyama, T., Koide, N., Mu, M. M., Yoshida, T. and Yokochi, T. The inhibitory action of sodium arsenite on lipopolysaccharide-induced signaling. J. Immunol, 166:2011-7, 2001.
Chen, H., Chang, S., Trub, T. and Neel, B. G. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol, 16: 3685-3697, 1996.
Chou, T. C. and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inbitors. Adv Enzyme Regul, 22: 27-55, 1984.
Church, D., Zhang, Y., Rago, R. and Wilding, G. Efficacy of suramin against human prostate carinoma DU145 xenografts in nude mice. Cancer Chemother Pharmacol, 43: 198-204, 1999.
Collins, S. J., Ruscetti, F. W., Gallagher, R. E. and Gallo, R. C. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J. Exp Med., 149:969-74, 1979.
Cyster, J. G. and Goodnow, C. C. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity, 2 13-24, 1995.
Damen, J. E., Cutler, R. L., Jiao, H., Yi, T. and Krystal, G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (P1) 3-kinase and for EpR-associated PI 3-kinase activity. J. Biol Chem, 270: 23402-23408, 1995.
David, M., Chen, H. E., Goelz, S., Larner, A. C. and Neel, B. G. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell Biol, 15: 7050-7058, 1995.
de Bruijn P, Kehrer DF, Verweij J, Sparreboom A. Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. J Chromatogr B Biomed Sci Appl. Apr. 5, 2001;753(2):395-400.
Denu, J. M. and Dixon, J.
Chowdhury Iqbal
Morgan & Lewis & Bockius, LLP
Prouty Rebecca E.
The Cleveland Clinic Foundation
LandOfFree
Therapeutic compositions and methods useful in modulating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions and methods useful in modulating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions and methods useful in modulating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015628